Incannex Healthcare (IXHL) risk factors, FY2025 10-K

Risks Related to Our Financial Condition and Capital Requirements

1. 01We have a history of operating losses and may not achieve or maintain profitability in the future. Our ability to achieve profitability depends on the successful development of our drug candidates40% rewritten
2. 02We rely on R&D tax incentives to provide resources to conduct our business operations. If the amount of R&D tax incentives decreases, our results of operations and cash resources may be materially affected
3. 03We will need to obtain additional funding in connection with the further development of our drug candidates23% rewritten
4. 04If we fail to maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results or prevent fraud, which could have a material adverse effect on our stock price
5. 05This material weakness will not be considered remediated until we have completed implementing the necessary additional applicable controls and operate with these controls for a sufficient period of time to allow management and our auditors to conclude that these controls are operating effectively89% rewritten
6. 06We cannot guarantee that our share repurchase program will be utilized to the full value approved, if at all, or that it will enhance long-term stockholder value. Any repurchases we consummate could increase the volatility of the price of our common stock and could have a negative impact on our available cash balanceNew

Risks Related to the Development and Regulatory Approval of Our Drug Candidates

1. 07If we do not obtain the necessary regulatory approvals, we will be unable to commercialize our drug candidates
2. 08Many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of marketing approval for our drug candidates86% rewritten
3. 09The ongoing and future clinical trials of our drug candidates may not show sufficient safety and efficacy to obtain requisite regulatory approvals for commercial sale
4. 10Our drug candidates may cause undesirable side effects that could delay or prevent their marketing approval, limit their commercial potential, or result in significant negative consequences following marketing approval, if marketing approval is obtained
5. 11Topline, interim or preliminary data from our trials may not be representative of final results
6. 12If our candidates are approved, we would likely need to rapidly scale our manufacturing capabilities, including any capability we may have through our CMOs. If our CMOs fail to scale as needed, our commercialization efforts, or the commercialization efforts of any partner we may have, would likely be impaired
7. 13We rely on third parties to conduct our preclinical and clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our drug candidates and our business could be substantially harmed
8. 14A potential breakthrough therapy designation by the FDA for our drug candidates may not lead to a faster development or regulatory review or approval process, and it does not increase the likelihood that our drug candidates will receive marketing approval
9. 15We may seek Fast Track designation for one or more of our other drug candidates in the future. Even if we apply for Fast Track designation in the future, we might not receive such designation, and even if we do, such designation may not actually lead to a faster development or regulatory review or approval process
10. 16We may use our financial and human resources to pursue a particular research program or drug candidate and fail to capitalize on programs or drug candidates that may be more profitable or for which there is a greater likelihood of success
11. 17We have conducted, and intend to conduct, clinical trials for certain of our drug candidates at sites outside of the United States, and the U.S. regulatory agencies may not accept data from trials conducted in such locations

Risks Related to Commercialization of Our Drug Candidates

1. 18Future potential sales of our drug candidates may suffer if they are not accepted in the marketplace by physicians, patients and the medical community
2. 19We face competition from entities that may develop drug candidates for our target disease indications and from entities currently providing treatment to our target disease indications24% rewritten
3. 20Our drug candidates for which we obtain approval may face competition sooner than anticipated
4. 21Even if we are able to commercialize any of our drug candidates, such products may become subject to unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives, which would harm our business
5. 22The testing, marketing and sale of therapeutic products entails an inherent risk of product liability. We rely on a number of third-party researchers and contractors to produce, collect, and analyze data regarding the safety and efficacy of our drug candidates
6. 23Product shipment delays could have a material adverse effect on our business, results of operations and financial condition
7. 24Our drug candidates will be subject to controlled substance laws and regulations. Failure to receive necessary approvals may delay the launch of our drug candidates and failure to comply with these laws and regulations may adversely affect the results of our business operations
8. 25Our relationships with customers and third-party payors will be subject to applicable anti-kickback, fraud and abuse and other healthcare laws and regulations, which could expose us to criminal sanctions, substantial civil penalties, contractual damages, reputational harm and diminished profits and future earnings
9. 26Changes in U.S. healthcare law and implementing regulations, as well as changes in healthcare policy, may impact our business in ways that we cannot currently predict and may harm our business and results of operations
10. 27Our drug candidates contain cannabinoid and psychedelic substances, the use of which may generate public controversy. Adverse publicity or public perception regarding our current or future drug candidates may negatively influence the success of these therapies
11. 28The production and sale of our drug candidates may be considered illegal or may otherwise be restricted due to the use of controlled substances, which may have consequences for the legality of investments from international jurisdictions

Risks Related to Our Business Operations

1. 29Our R&D efforts will be jeopardized if we are unable to retain key personnel and cultivate key academic and scientific collaborations
2. 30Inflation may adversely affect us by materially increasing our costs
3. 31Changes in interpretation or application of account principles generally accepted in the United States (“US GAAP”) may adversely affect our operating results96% rewritten
4. 32Our business activities may be subject to the Foreign Corrupt Practices Act (“FCPA”) and similar anti-bribery and anti-corruption laws of other countries in which we operate
5. 33We incur, and will continue to incur, costs and expect significantly increased costs as a result of operating as a public company, and our management is now required to devote substantial time to new compliance initiatives
6. 34We are exposed to fluctuations in exchange rates which may adversely affect our operating results
7. 35There is a scarcity of experienced professionals in our industry. If we are not able to retain and recruit personnel with the requisite technical skills, we may be unable to successfully execute our business strategy
8. 36We or the third parties upon whom we depend may be adversely affected by geopolitical events, accidents, conflicts, medical epidemics or pandemics, extreme weather or other natural disasters55% rewritten

Risks Related to Intellectual Property

1. 37Our success depends on our ability to protect our intellectual property and our proprietary technology, and we may not be able to protect our intellectual property rights throughout the world
2. 38Intellectual property rights of third parties could adversely affect our ability to commercialize our drug candidates, such that we could be required to litigate with or obtain licenses from third parties in order to develop or market our drug candidates
3. 39Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed
4. 40We could be required to incur significant expenses to obtain our intellectual property rights, and we cannot ensure that we will obtain meaningful patent protection for our drug candidates
5. 41Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements
6. 42We may become involved in lawsuits to protect and defend our patents or other intellectual property, which could be expensive, time consuming and unsuccessful
7. 43Issued patents covering our drug candidates, compositions or uses could be found invalid or unenforceable if challenged in a patent office or court
8. 44The patent protection and patent prosecution for some of our drug candidates may in the future be dependent on third parties
9. 45Confidentiality and invention assignment agreements with our employees, advisors and consultants may not adequately prevent disclosure of trade secrets and protect other proprietary information
10. 46We may be subject to claims that our employees, consultants or independent contractors wrongfully used or disclosed alleged confidential information of third parties or that our employees wrongfully used or disclosed alleged trade secrets of their former employers
11. 47Intellectual property rights do not address all potential threats to our competitive advantage
12. 48Changes in patent law could diminish the value of patents in general, thereby impairing our ability to protect our drug candidates and any future drug candidates
13. 49We may not have sufficient patent term or regulatory exclusivity protections for our drug candidates to effectively protect our competitive position
14. 50If we are unable to obtain and maintain patent protection for any drug candidates, our competitors could develop and commercialize products or technology similar or identical to ours, and our ability to successfully commercialize any drug candidates we may develop, and our technology may be adversely affected
15. 51Price controls may be imposed in non-U.S. markets, which may negatively affect our future profitability

Risks Related to Investing in Our Securities

1. 52The price of our common stock has been and may continue to be highly volatile, which may make it difficult for stockholders to sell our common stock when desired or at attractive prices
2. 53U.S. investors may have difficulty enforcing civil liabilities against our directors or members of senior management
3. 54Certain provisions of our amended and restated certificate of incorporation may discourage, delay or prevent a change in control of our company and, therefore, depress the trading price of our securities51% rewritten
4. 55We do not anticipate paying any cash dividends on our capital stock in the foreseeable future; capital appreciation, if any, will be your sole source of gain as a holder of our common stock93% rewritten
5. 56If securities or industry analysts do not publish, or cease publishing, research or reports, or publish unfavorable research or reports, about us, our business or our market, or if they change their recommendations regarding our stock adversely, our stock price and trading volume could decline
6. 57Having availed ourselves of scaled disclosure available to smaller reporting companies, we cannot be certain if such reduced disclosure will make our common stock less attractive to investors63% rewritten
7. 58We may become involved in securities litigation that could materially divert management’s attention and harm our business, and insurance coverage may not be sufficient to cover all costs and damages
8. 59We are and may continue to be subject to short selling strategiesNew
9. 60Our amended and restated bylaws provide that we will indemnify our directors and officers, in each case to the fullest extent permitted by Delaware law